Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.
The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.
Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.
For more information, please visit Twist Bioscience.
Rhea-AI Summary
Twist Bioscience (NASDAQ: TWST) launches a new Human Pangenome Spike-in for the Twist Exome 2.0 panel to enhance genetic variation detection during whole exome sequencing. The tool aims to provide a more comprehensive view of human genetic diversity, leveraging the Human Pangenome Reference Consortium's diverse genomic data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announces CE-marked Precision Dx Products compliant with EU IVDR regulations, including Twist Precision Prep and Enrichment Dx Kit, Twist Precision Exome Dx Panel, and Twist Precision Exome Dx Kit. The products aim to facilitate panel sequencing within clinical settings, meeting high quality standards. Twist collaborates with Platomics to streamline documentation generation and regulatory compliance. CEO Emily M. Leproust highlights the significance of IVDR certification for diagnostic tests and the company's commitment to supporting European customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
-
Rhea-AI Summary
Twist Bioscience Corporation (TWST) executives will participate in fireside chats at upcoming investor conferences, including TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference. The chats will be webcast live and available for replay for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
Rhea-AI Summary
Twist Bioscience Corporation (TWST) announced the grant of 122,400 restricted stock units (RSUs) to 36 recently hired individuals as an employment inducement. The RSUs vest over a 48-month period, with 25% vesting on the one year anniversary of the start date of the employee, and 1/16 of the RSUs vesting on each quarterly anniversary thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
-
News
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) and Element Biosciences, Inc. announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System. The collaboration aims to offer customers an economical and streamlined approach to next generation sequencing. The Exome 2.0 panel and high performing library preparation and target enrichment reagents are designed to provide best-in-class sequencing, detect rare and inherited diseases, and germline cancers. The purpose-built solution for Element’s AVITI chemistry will reduce per sample sequencing requirements, potentially saving downstream sequencing costs. The companies have ambitious product roadmaps for 2024 to make sequencing even easier for labs to produce the highest quality data at a low cost.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
-
Rhea-AI Summary
Twist Bioscience Corporation (TWST) has launched the cfDNA Library Preparation Kit to enable liquid biopsy research, addressing challenges associated with library preparation from circulating cfDNA with reliable and robust performance from as little as 1ng sample input. The kit can detect rare allele variants due to its high conversion rate and protocols minimize sample handling for a streamlined workflow and results delivered within two hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
News
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announced the early access of the Twist Flex Prep Ultra High-Throughput (UHT) Kit, a novel technology that aims to enable unparalleled throughput at a fraction of the cost of existing on-market solutions. The kit utilizes novel chemistry that accepts and self-normalizes a wide range of sample input amounts through a new proprietary Normalization By Ligation (NBL) technology, crucial for researchers in AgBio who sequence thousands of samples of varying inputs. The technology is positioned to drive NGS adoption in agricultural genomics, enabling streamlined, scalable, and cost-effective workflows for high-throughput applications in breeding, trait selection, and other research areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) reported record revenue of $71.5M in 1QFY24, a 32% increase over 1QFY23. Orders increased to $77.5M, a 19% increase over 1QFY23. The company raised its FY 2024 revenue guidance to $288M to $293M and increased FY 2024 gross margin guidance to 40% to 41%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.01%
Tags
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) has expanded its Twist Express Genes service to include larger DNA preparations, offering rapid gene synthesis at all gene prep scales, enabling large scale experimentation for pharmaceutical, biotechnology, academic, and industrial chemical researchers. The service has received positive feedback from customers for its consistent and rapid turnaround time. The company leverages its silicon-based DNA synthesis platform to deliver Clonal Genes and Gene Fragments at scale and with rapid turnaround times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
News
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) will issue its financial results for the fiscal 2024 first quarter on February 2, 2024. The company plans to hold a conference call and live audio webcast to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website. The conference call will be webcast live and the webcast replay will be available for two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
FAQ
What is the current stock price of Twist Bioscience (TWST)?
The current stock price of Twist Bioscience (TWST) is $37.11 as of March 3, 2025.
What is the market cap of Twist Bioscience (TWST)?
The market cap of Twist Bioscience (TWST) is approximately 2.2B.
What does Twist Bioscience Corporation do?
Twist Bioscience specializes in synthetic DNA production, utilizing a proprietary semiconductor-based platform to create high-quality DNA efficiently.
How does Twist Bioscience's technology differ from traditional methods?
Twist Bioscience uses a 10,000-well silicon platform instead of traditional 96-well plastic plates, offering faster, cost-effective, and high-throughput DNA synthesis.
What are some applications of Twist Bioscience's synthetic DNA?
Applications include personalized medicine, sustainable chemical production, improved agriculture, in vivo diagnostics, biodetection, and data storage.
Where does Twist Bioscience generate most of its revenue?
Twist Bioscience primarily generates its revenue from the United States.
How does Twist Bioscience contribute to personalized medicine?
By providing rapid and high-quality DNA synthesis, Twist Bioscience accelerates the development of personalized medical treatments.
What is the significance of using silicon in DNA synthesis?
Using silicon allows Twist Bioscience to overcome inefficiencies in traditional DNA production, enabling faster and more cost-effective synthesis.
Can Twist Bioscience's technology be used in agriculture?
Yes, the synthetic DNA tools can improve agricultural production by enabling the development of better crops and agricultural methods.
What ongoing projects does Twist Bioscience have?
Twist Bioscience is involved in various projects across personalized medicine, sustainable chemical production, and new applications such as in vivo diagnostics and data storage.
How does Twist Bioscience's platform support researchers?
The platform provides researchers with high-throughput, high-quality synthetic DNA, enabling them to quickly explore and develop new opportunities.
Where can I find more information about Twist Bioscience?
Additional information is available on their official website: www.twistbioscience.com.
Twist Bioscience
Nasdaq:TWST
TWST Rankings
TWST Stock Data
2.23B
58.34M
1.94%
110.12%
15.4%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
United States
SOUTH SAN FRANCISCO